Barclays Raises PT on Hims & Hers Health (HIMS) Stock

Core Viewpoint - Hims & Hers Health, Inc. is identified as one of the most shorted stocks to buy in 2026, with a recent price target increase from Barclays indicating strong market potential following a collaboration with Novo Nordisk [1][2]. Group 1: Stock Performance and Analyst Ratings - Barclays analyst Glen Santangelo raised the price objective for Hims & Hers Health's stock to $29 from $25, maintaining an "Overweight" rating, reflecting confidence in the company's growth potential [1]. - The increase in share price after the Novo Nordisk agreement highlights a significant market opportunity for Hims & Hers Health [1][2]. Group 2: Legal and Market Opportunities - The collaboration with Novo Nordisk signifies the removal of legal overhang for Hims & Hers Health's stock, suggesting that the market has been undervaluing the company's potential from new product offerings [2]. - The company plans to provide access to a range of FDA-approved GLP-1 medications and compounded semaglutide, indicating a strategic move into the weight loss care market [3]. Group 3: Company Overview - Hims & Hers Health operates as a consumer-first health and wellness platform, connecting consumers with licensed healthcare professionals [4].